It is an old chestnut regarding patents. i understand newer investors may have a concern.
The composition of matter patent has been held by Elanco, but is due to expire in most jurisdictions this year.
PAA hold multiple patents for the use of monepantel for numerous indications through their subsidiary company Pitney Pharmaceuticals.
These include neuro-degenerative diseases, human cancers, anti-virals and canine lymphomas. All our patents have a long runway.
There are no impediments to PAA pursuing it's clinical program and negotiation of commercial deals.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-206
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.015(8.11%) |
Mkt cap ! $98.34M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $66.44K | 346.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 86359 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 107894 | 5 |
View Market Depth
| Last trade - 15.42pm 13/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |